Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10750777)

  • 1. Molecular biologic substaging of stage I lung cancer according to gender and histology.
    D'Amico TA; Aloia TA; Moore MB; Herndon JE; Brooks KR; Lau CL; Harpole DH
    Ann Thorac Surg; 2000 Mar; 69(3):882-6. PubMed ID: 10750777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.
    D'Amico TA; Massey M; Herndon JE; Moore MB; Harpole DH
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):736-43. PubMed ID: 10096969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.
    Harpole DH; Richards WG; Herndon JE; Sugarbaker DJ
    Ann Thorac Surg; 1996 May; 61(5):1470-6. PubMed ID: 8633961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
    Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
    J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.
    Kwiatkowski DJ; Harpole DH; Godleski J; Herndon JE; Shieh DB; Richards W; Blanco R; Xu HJ; Strauss GM; Sugarbaker DJ
    J Clin Oncol; 1998 Jul; 16(7):2468-77. PubMed ID: 9667266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.
    Ahrendt SA; Hu Y; Buta M; McDermott MP; Benoit N; Yang SC; Wu L; Sidransky D
    J Natl Cancer Inst; 2003 Jul; 95(13):961-70. PubMed ID: 12837832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
    Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
    J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
    Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
    J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
    Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
    Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.
    Chansky K; Sculier JP; Crowley JJ; Giroux D; Van Meerbeeck J; Goldstraw P;
    J Thorac Oncol; 2009 Jul; 4(7):792-801. PubMed ID: 19458556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiƶ J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of S100A13 protein is associated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer.
    Miao S; Qiu T; Zhao Y; Wang H; Sun X; Wang Y; Xuan Y; Qin Y; Jiao W
    Thorac Cancer; 2018 Sep; 9(9):1136-1144. PubMed ID: 30047626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
    Sakurai H; Asamura H; Goya T; Eguchi K; Nakanishi Y; Sawabata N; Okumura M; Miyaoka E; Fujii Y;
    J Thorac Oncol; 2010 Oct; 5(10):1594-601. PubMed ID: 20736855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do molecular markers predict survival in non-small-cell lung cancer?
    Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.
    Ohsaki Y; Tanno S; Fujita Y; Toyoshima E; Fujiuchi S; Nishigaki Y; Ishida S; Nagase A; Miyokawa N; Hirata S; Kikuchi K
    Oncol Rep; 2000; 7(3):603-7. PubMed ID: 10767376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.